Investigating Medication vs. Prostatic Urethral Lift: 3-Month Results of the IMPACT Trial

Technical Summary: Investigating Medication vs. Prostatic Urethral Lift (IMPACT Trial)

Problem Statement
Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) affect a significant portion of men over age 50. While medical therapy, particularly alpha-blockers like tamsulosin, is the standard of care for many, it presents notable limitations: up to 71% of patients discontinue medication within one year, and nearly half report no clinically significant symptom improvement. Furthermore, medical therapy is associated with side effects such as sexual dysfunction, dizziness, and nasal congestion. Conversely, minimally invasive surgical therapies (MISTs) like Prostatic Urethral Lift (PUL) offer a procedure-based alternative with established safety and durability profiles. However, direct head-to-head randomized comparisons between PUL and standard medical therapy have been limited, making it difficult to guide shared decision-making based on comparative efficacy and safety data.

Methodology
The IMPACT trial is a prospective, multicenter, 1-to-1 non-blinded randomized controlled trial (RCT) conducted across 13 sites in the United States.

• Population: Men aged 45 or older with symptomatic BPH who were willing to wash out of prior BPH medications.
• Intervention: Subjects were randomized to either Prostatic Urethral Lift (PUL) or daily tamsulosin (0.4 mg).
• Study Design: The primary endpoint was the change in International Prostate Symptom Score (IPSS) at 3 months. The study was designed to test for non-inferiority of PUL against tamsulosin with a margin of 12%.
• Analysis: Efficacy was analyzed on the per-protocol (PP) population, while safety was analyzed on the safety population (all randomized subjects receiving at least one dose or implant). Secondary endpoints included Quality of Life (QoL), sexual function (IIEF, MSHQ), urinary flow rate (Qmax), and medication adherence.
• Crossover: After the 3-month assessment, subjects were permitted to cross over to the alternative therapy if treatment goals were not met.

Key Results

• Efficacy (IPSS): PUL demonstrated significantly superior symptom relief compared to tamsulosin. At 3 months, the PUL group experienced a 46% improvement in IPSS, compared to a 16% improvement in the tamsulosin group (p < 0.001). The median percent change was −54.7% for PUL versus −16.0% for tamsulosin. Non-inferiority was met, and post-hoc analysis confirmed PUL superiority.
• Quality of Life (QoL): QoL scores improved by 47% in the PUL group versus 24% in the medication group at 3 months (p < 0.001).
• Sexual Function: Sexual function was largely preserved in both groups. However, the PUL group showed significant improvements in ejaculatory function (MSHQ-EjD function improved by 58% vs. 4.9% for medication; p < 0.001) and total IIEF scores (27% improvement vs. a nominal 1.4% reduction for medication). No new cases of erectile dysfunction were reported in the medication cohort, and only one transient case occurred in the PUL cohort.
• Safety and Adverse Events (AEs): Both groups experienced mostly mild-to-moderate AEs. PUL-related AEs were concentrated in the peri-procedural period (67% occurred within 2 days), whereas medication-related AEs accrued throughout the follow-up period. One serious adverse event (pelvic hematoma) occurred in the PUL group.
• Adherence: While 91% of medication subjects self-reported adherence at 3 months, objective pill counts revealed only 80% adherence. Common reasons for non-adherence included side effects (nasal congestion, dizziness, sexual issues) and lack of symptom improvement.
• Composite Outcomes: When combining symptom improvement and safety, 87.3% of PUL subjects were classified as responders compared to 38.2% of medication subjects. Furthermore, 55.9% of PUL subjects achieved clinically meaningful symptom improvement without adverse events, compared to 30.1% in the medication group.

Significance and Claims
The authors claim that the IMPACT trial is the largest RCT to date directly comparing a MIST (PUL) to standard medical therapy for BPH. The study concludes that PUL provides significantly greater symptom relief, quality-of-life improvement, and patient satisfaction than tamsulosin within the first 3 months of treatment.

Key claims regarding the study's contribution include:

1. Superiority in Early Outcomes: PUL offers nearly triple the symptom improvement of tamsulosin at 1 and 3 months.
2. Sexual Function Preservation: The procedure preserves and potentially improves ejaculatory function, addressing a common concern with medical therapy.
3. Real-World Applicability: By utilizing broad inclusion criteria, the trial reflects a real-world patient population, enhancing the external validity of the findings.
4. Value of Procedure-Based Therapy: The results highlight the limitations of pharmacologic therapy regarding adherence and side effects, reinforcing the clinical value of definitive, procedure-based therapies for patients seeking durable relief without lifelong daily medication.
5. Shared Decision-Making: The findings support a goal-oriented approach to care, where treatment success is defined not just by symptom scores but by the ability to achieve personal health goals, including sexual health and freedom from daily medication.

The paper acknowledges limitations, including the short-term follow-up (3 months for primary endpoints), the open-label design (due to ethical concerns regarding sham procedures), and the potential for selection bias among patients willing to be randomized to a procedure. The study notes that long-term durability data for PUL (up to 5 years) exists from prior studies, but this specific trial will not test the long-term durability of tamsulosin due to high crossover rates.